Pharsight

Qudexy Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10363224 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)

US9555005 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)

US9101545 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)

US8889190 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)

US8652527 UPSHER SMITH LABS Extended-release topiramate capsules
Mar, 2033

(8 years from now)

Qudexy Xr is owned by Upsher Smith Labs.

Qudexy Xr contains Topiramate.

Qudexy Xr has a total of 5 drug patents out of which 0 drug patents have expired.

Qudexy Xr was authorised for market use on 11 March, 2014.

Qudexy Xr is available in capsule, extended release;oral dosage forms.

Qudexy Xr can be used as treatment of seizures.

The generics of Qudexy Xr are possible to be released after 19 March, 2033.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of QUDEXY XR before it's drug patent expiration?
More Information on Dosage

QUDEXY XR family patents

Family Patents